I[NTRODUCTION]{.smallcaps} {#sec1-1}
==========================

Multiple sclerosis (MS; MIM 126200) is a common, partially heritable central nervous system (CNS) autoimmune disorder being considered as one of the most common causes of neurological disability in young adults.\[[@ref1][@ref2]\] Relapsing-remitting MS (RRMS) is the most common form of MS which has a biphasic disease course characterized by alternating episodes of acute neurological deficits, followed by a complete or partial recovery. Although the exact pathogenesis of MS is still not well classified, it is no doubt that genetic factors are primarily responsible for the substantially increased frequency of the disease, especially in the relatives of affected individuals.\[[@ref3][@ref4][@ref5]\] For years, the major histocompatibility complex (MHC) was the only known MS susceptibility region.\[[@ref6]\] However, hundreds of variants outside MHC region had now been identified by several genome-wide association studies (GWASs).\[[@ref7][@ref8]\]

The major pathogenic process of MS mainly starts with the activation of autoreactive lymphocytes and their migration across the blood-brain barrier. Transcription factors (TFs) are a group of key regulators involving in controlling lineage differentiation and cell survival. Certainly, TFs are indispensable for the T helper (Th) cell fate determination and cytokine production. A number of previous studies have demonstrated that the dysregulation of TFs is deeply involved in the pathogenesis of MS.\[[@ref9][@ref10][@ref11]\] In addition, a series of GWAS analyses had discovered several risk loci within transcription regulation genes. In 2011, a Caucasian population-based multicenter GWAS analysis reported at least eight transcription regulator-related risk loci among 29 novel MS susceptibility loci.\[[@ref7]\] Later on, another GWAS analysis replicated these results in a larger cohort.\[[@ref8]\] In addition, it has been indicated that the mRNA expression of one TF, *EOMES*, was significantly and consistently lower in MS patients comparing to healthy controls (HCs).\[[@ref12]\]

However, to date, few analyses were conducted to identify the variants located in transcription regulation genes in Asian MS populations. Here, we performed a MassArray Assay to genotype the previously reported variants located in the transcription regulation genes in order to elucidate their role in the Chinese MS patients.

M[ETHODS]{.smallcaps} {#sec1-2}
=====================

Ethical approval {#sec2-1}
----------------

The written informed consent was signed by each participant before inclusion in the study. This study was approved by the Ethics Committee of Huashan Hospital of Fudan University, the Second Affiliated Hospital of Zhejiang University School of Medicine, and the First Affiliated Hospital of Fujian Medical University.

Subjects {#sec2-2}
--------

In the first stage, a total of 142 MS patients (59 males, 83 females; mean age 39.8 ± 12.3 years; range: 13.0--66.0 years) were consecutively collected from September 2, 2008, to June 7, 2013. All patients underwent detailed neurological examinations, laboratory tests, and magnetic resonance imaging scans for the brain and/or spinal cord. Patients were then diagnosed according to the revised McDonald criteria.\[[@ref13][@ref14]\] In addition, 301 healthy individuals (175 males, 126 females; mean age 37.0 ± 15.6 years; range 16.0--85.0 years) with no history of autoimmune diseases were recruited as HCs matched for case ethnicity and region. To validate the positive result from the first stage, another 44 RRMS patients and 200 HCs were consecutively collected from April 7, 2015, to June 29, 2017.

Genotyping {#sec2-3}
----------

Genomic DNA was extracted from peripheral blood mononuclear cell using a QIAamp DNA Blood Minikit (QIAGEN, Hilden, Germany). Eight previously reported TF-related variants were genotyped using the Sequenom MassArray system. MassArray Assay Design 3.1 software (Sequenom, San Diego, USA) was used to design the polymerase chain reaction primers used in the genotyping \[[Supplementary Table 1](#T1){ref-type="table"}\]. Alleles were detected using a matrix-assisted laser desorption/ionization time of flight mass spectrometry platform (MassArray™, Sequenom Inc., San Diego, CA, USA) according to a previously described method.\[[@ref15]\] In validation of the first stage, rs11129295 was further Sanger sequenced in subjects recruited for the second stage using a pair of in-house designed primer (Forward: 5\'-TCTTGTTTTCTGGAGAGGAGC-3\'; Reverse: 5\'-ACCCACCTTCAGGAATTTCAAT-3\').

###### 

Primers for MassArray

  SNP                                       Candidate gene   PCR primers                               MassEXTEND primers
  ----------------------------------------- ---------------- ----------------------------------------- ---------------------------
  rs228614                                  *NFKB1/MANBA*    Forward: ACGTTGGATGTGCTTTTACTGTGTTCCTTC   GTCCCATTCAGTGCTTTC
  Reverse: ACGTTGGATGAGTCAGGCTTAAGCAACCAC                                                              
  rs744166                                  *STAT3*          Forward: ACGTTGGATGACATTGAGAGGGCAATTGGG   gggcCTTGAGGGAATCGAGC
  Reverse: ACGTTGGATGTGGCTGTAATGTCTTGAGGG                                                              
  rs2300603                                 *BATF*           Forward: ACGTTGGATGACATAGACTGATGCCGAGAG   cctctTCAGTATGAGGCTTTCATTC
  Reverse: ACGTTGGATGTTCTCTCTAAGCAGCCATCC                                                              
  rs4410871                                 *MYC*            Forward: ACGTTGGATGTCTGCCGTGAATGAGAAACC   CCTCCCACACTGGAA
  Reverse: ACGTTGGATGGCAGTTACATCTGCAGTGTG                                                              
  rs4902647                                 *ZFP36L1*        Forward: ACGTTGGATGTAAGCCTATAGCTCCCTTCC   caCCCGTCCCCTCTAAG
  Reverse: ACGTTGGATGGCTCCTTTGCAGAAAACCTC                                                              
  rs9321619                                 *OLIG3*          Forward: ACGTTGGATGCATCTCTTGTAGTCTGGAGG   CAACTGGGCAGATGG
  Reverse: ACGTTGGATGGGGCAGGAAGAGCATTAAAG                                                              
  rs11129295                                *EOMES*          Forward: ACGTTGGATGGCTCATTTAATCTTCACAAC   cctcGGCCAGTTTTCTAACTTCT
  Reverse: ACGTTGGATGGTGACGTGGCCAGTTTTCTA                                                              
  rs11154801                                *MYB/AHI1*       Forward: ACGTTGGATGAGCTGTCATGTACCATGCAC   ccttaAGAAGGTCGAAACCTCAAGT
  Reverse: ACGTTGGATGCTCCTTCAGAAGGTCGAAAC                                                              

PCR: Polymerase chain reaction; SNP: Single-nucleotide polymorphisms.

Statistical analyses {#sec2-4}
--------------------

Quantitative measures were summarized with descriptive statistics, such as mean ± standard deviation (SD) and 95% confidence interval (*CI*) of mean. Difference in ages was measured using the Student\'s *t*-test. Differences in genders, allele and genotype frequencies between MS and HC, odds ratios (*OR* s), and 95% *CI* s were calculated using the Chi-square test or Fisher\'s exact test. Hardy-Weinberg equilibrium (HWE) was tested using the Chi-squaretest. Statistical analyses were performed using SPSS 19.0 software (SPSS Inc., Chicago, IL, USA) and GraphPad Prism 6.02 (GraphPad Inc, San Diego, CA, USA). The criterion for a signifcant difference was a value of *P* \< 0.05.

R[ESULTS]{.smallcaps} {#sec1-3}
=====================

Demographic data {#sec2-5}
----------------

The demographic data are summarized in [Table 1](#T2){ref-type="table"}. In stage 1, the average ages of the MS patients and HCs were 39.8 ± 12.3 and 37.0 ± 15.6 years, respectively (*t* = 1.840, *P* = 0.070). In stage 2, the average ages of the MS patients and HCs were 39.0 ± 13.8 and 33.3 ± 11.3 years, respectively (*t* = 2.740, *P* = 0.007). In total, the average ages of the MS patients and HCs were 39.6 ± 12.5 and 35.5 ± 14.2 years, respectively (*t* = 3.310, *P* = 0.001).

###### 

Demographic and clinical characteristics of RRMS patients and healthy controls

  Characteristics          MS            HC            Statistics   *P*
  ------------------------ ------------- ------------- ------------ -------
  Stage 1, *N*             142           301                        
   Male/female, *n*        59/83         175/126       10.656\*     0.001
   Age (year), mean ± SD   39.8 ± 12.3   37.0 ± 15.6   1.840^†^     0.070
  Stage 2, *N*             44            200                        
   Male/female, *n*        17/27         98/102        1.555\*      0.210
   Age (year), mean ± SD   39.0 ± 13.8   33.3 ± 11.3   2.740^†^     0.007
  Stage 1 + Stage 2, *N*   186           501                        
   Male/female, *n*        76/110        273/228       10.083\*     0.001
   Age (year), mean ± SD   39.6 ± 12.5   35.5 ± 14.2   3.310^†^     0.001

\**χ*^2^; ^†^*t*. MS: Multiple sclerosis; RRMS: Relapsing-remitting MS; HC: Healthy controls; SD: Standard deviation.

*EOMES* variant rs11129295 associated with increasing risk in Chinese multiple sclerosis patients {#sec2-6}
-------------------------------------------------------------------------------------------------

The average genotyping success rate across the single-nucleotide polymorphisms (SNPs) was 97.5% using the Sequenom MassArray system. As shown in [Supplementary Table 2](#T3){ref-type="table"}, most of the SNPs in each group were under the HWE except *STAT3* variant rs744166 in MS patients (*P* = 0.020). Eventually, as summarized in [Table 2](#T4){ref-type="table"}, we found that the frequency of T/T genotype in *EOMES* variant rs11129295 was much higher in MS group with a significant difference (*χ*^2^ = 10.251, *P* = 0.005). In addition, the T allele of rs11129295 increased the risk of MS (*OR* = 1.764, *P* = 0.002). Besides, when analyzed in a dominant model, the genotype T/T and C/T together can increase the risk of MS (*OR* = 4.076, *P* = 0.019). Hence, it was a recessive model (*OR* = 1.776, *P* = 0.007). Furthermore, we replicated these findings in another group of population using Sanger sequencing. In this stage, we still found that the frequency of T/T genotype in rs11129295 was much higher in MS group with a significant difference (*P* = 0.020). Besides, the T allele increased the risk of MS (*OR* = 1.830, *P* = 0.030). However, we did not find significance in recessive model in stage 2 \[[Table 2](#T4){ref-type="table"}\].

###### 

Hardy-Weinberg equilibrium tests for all Chinese Han participants in this study

  SNP           Candidate gene   MS     HC            
  ------------- ---------------- ------ ------ ------ ------
  Stage 1                                             
   rs228614     *NFKB1/MANBA*    1.69   0.19   0.07   0.79
   rs744166     *STAT3*          5.95   0.02   2.66   0.10
   rs2300603    *BATF*           1.23   0.27   0.62   0.43
   rs4410871    *MYC*            1.09   0.30   1.82   0.18
   rs4902647    *ZFP36L1*        0.02   0.90   1.42   0.23
   rs9321619    *OLIG3*          0.48   0.49   0.01   0.92
   rs11129295   *EOMES*          0.77   0.38   0.13   0.72
   rs11154801   *MYB/AHI1*       1.72   0.19   0.92   0.34
  Stage 2                                             
   rs11129295   *EOMES*          2.91   0.09   2.16   0.14
  Stage 1 + 2                                         
   rs11129295   *EOMES*          2.67   0.10   1.64   0.20

MS: Multiple sclerosis; HC: Healthy controls.

###### 

Allele and genotype distributions of rs11129295 between MS and healthy controls

  SNP           Region       Candidate Gene   Genotype/Allele   MS, *n* (%)             HC, *n* (%)   *χ*^2^   *OR* (95% *CI*)   *P*
  ------------- ------------ ---------------- ----------------- ----------------------- ------------- -------- ----------------- -------------
  Stage 1                                                                                                                        
   rs11129295   Intergenic   *EOMES*          TT                91 (65.9)               157 (52.2)    10.251                     0.005
  CT            44 (31.9)    119 (39.5)                                                                                          
  CC            3 (2.2)      25 (8.3)                                                                                            
  T             226 (81.9)   433 (71.9)       10.022            1.764 (1.238--2.514)    0.002                                    
  C\*           50 (18.1)    169 (28.1)                                                                                          
  CT + TT^†^    135 (97.8)   276 (91.7)       5.958             4.076 (1.209--13.739)   0.019                                    
  CC            3 (2.2)      25 (8.3)                                                                                            
  TT^‡^         91 (65.9)    157 (52.2)       7.313             1.776 (1.169--2.769)    0.007                                    
  CT + CC       47 (34.1)    144 (47.8)                                                                                          
  Stage 2                                                                                                                        
   rs11129295   Intergenic   *EOMES*          TT                26 (59.1)               97 (48.5)     6.336                      0.020
  CT            18 (40.9)    78 (39)                                                                                             
  CC            0 (0)        25 (12.5)                                                                                           
  T             70 (79.5)    272 (68.0)       4.586             1.830 (1.046--3.200)    0.030                                    
  C\*           18 (20.5)    128 (32.0)                                                                                          
  CT + TT^†^    44 (100)     175 (87.5)       6.128             1.143 (1.085--1.204)    0.011                                    
  CC            0 (0)        25 (12.5)                                                                                           
  TT^‡^         26 (59.1)    97 (48.5)        1.618             1.534 (0.791--2.973)    0.203                                    
  CT + CC       18 (40.9)    103 (51.5)                                                                                          
  Stage 1 + 2                                                                                                                    
   rs11129295   Intergenic   *EOMES*          TT                117 (64.3)              254 (50.7)    17.452                     4.17×10^−5^
  CT            62 (34.1)    197 (39.3)                                                                                          
  CC            3 (1.6)      50 (10.0)                                                                                           
  T             296 (81.3)   705 (70.4)       16.378            1.834 (1.363--2.466)    5.19×10^−5^                              
  C\*           68 (18.7)    297 (29.6)                                                                                          
  CT + TT^†^    179 (98.4)   451 (90.0)       12.947            6.615 (2.037--21.481)   8.12×10^−5^                              
  CC            3 (1.6)      50 (10.0)                                                                                           
  TT^‡^         117 (64.3)   254 (50.7)       9.932             1.750 (1.233--2.484)    0.002                                    
  CT + CC       65 (35.7)    247 (49.3)                                                                                          

\*The C allele is the ancestral allele according to dbSNP build 141; ^†^Analysis in a dominant model; ^‡^Analysis in a recessive model. SNP: Single-nucleotide polymorphisms; MS: Multiple sclerosis; HC: Healthy controls. *CI*: Confidence interval; *OR*: Odds ratio.

In combined analyses of the two stages, we found that the frequency of T/T genotype in rs11129295 was much higher in MS group with a significant difference (*P* = 4.17 × 10^−5^), as well as the T allele increased the risk of MS (*OR* = 1.834, *P* = 5.19 × 10^−5^) and the higher frequency of T/T plus C/T in dominant model (*OR* = 6.615, *P* = 8.12 × 10^−5^) and T/T genotype in recessive model (*OR* = 1.750, *P* = 0.002; [Table 2](#T4){ref-type="table"}). As shown in [Table 3](#T5){ref-type="table"}, we did not find any other significant differences between MS and HC groups among other previously reported variants within transcription-related genes.

###### 

Other variants involved in transcription regulation between MS and healthy controls

  SNP          Location\*            Region                Candidate gene             
  ------------ --------------------- --------------------- ---------------- --------- -------------------------
  rs228614     Chr4: 102657480       Intronic              *NFKB1/MANBA*              
  rs11154801   Chr6: 135418217       Intronic              *MYB/AHI1*                 
  rs9321619    Chr6: 137553271       Intergenic            *OLIG3*                    
  rs4410871    Chr8: 127802783       Intronic              *MYC*                      
  rs4902647    Chr14: 68787474       Downstream            *ZFP36L1*                  
  rs2300603    Chr14: 75539214       Intronic              *BATF*                     
  rs744166     Chr17: 42362183       Intronic              *STAT3*                    
                                                                                      
  **SNP**      **MS MAF (allele)**   **HC MAF (allele)**   ***χ*^2^**       ***P***   ***OR* (95% *CI***)
                                                                                      
  rs228614     0.48 (A)              0.48 (G)              1.005            0.361     0.864 (0.649--1.150)^†^
  rs11154801   0.36 (A)              0.35 (A)              0.067            0.796     1.040 (0.771--1.404)
  rs9321619    0.36 (A)              0.39 (A)              0.559            0.455     0.894 (0.665--1.200)
  rs4410871    0.30 (T)              0.34 (T)              1.205            0.272     0.842 (0.620--1.144)
  rs4902647    0.30 (C)              0.33 (C)              0.648            0.421     0.881 (0.648--1.199)
  rs2300603    0.31 (C)              0.27 (C)              2.139            0.144     1.260 (0.924--1.719)
  rs744166     --                    --                    --                         --

\*Position is based on GRCh38.p10 and dbSNP Build 141; ^†^For Allele A. MS: Multiple sclerosis; HC: Healthy controls; SNP: Single-nucleotide polymorphisms; *CI*: Confidence interval; --: Not available; MAF: Minor allele frequency; *OR*: Odds ratio.

D[ISCUSSION]{.smallcaps} {#sec1-4}
========================

MS is an autoimmune demyelinating disease of CNS. Increasing number of evidences hint that MS is strongly associated with genetics. The MHC loci made the early success in demonstrating the important role of genetic factors. To date, 13 MHC loci had been identified.\[[@ref6]\] Nevertheless, little progress was made in unraveling the non-MHC genes underlying susceptibility to MS until the advent of GWAS technology. Over the last decade, over 200 non-MHC genes had been identified using GWAS analyses in large cohorts.\[[@ref7][@ref8][@ref16]\] Unfortunately, almost all the GWAS analyses were Caucasian population based. A number of risk loci might not be replicated in Chinese MS patients. In our previous studies, Liu *et al.*\[[@ref17]\] found that the variants of interferon regulatory factor 5 were not associated with MS in the southeastern Han Chinese population. Moreover, Cai *et al.*\[[@ref18]\] found the association between autophagy-related gene 5 (*ATG5*) and neuromyelitis optica, but failed in MS. Fortunately, Zhuang *et al.*\[[@ref19][@ref20]\] identified that the variants in interleukin 7 (*IL7*) and *CYP27B1* were associated with MS. Similarly, in the present study, we confirmed only one previously reported risk variant, rs11129295 in *EOMES* gene. We found that the frequency of T/T genotype was much higher in the MS group and the T allele of rs11129295 increased the risk of MS.

TFs are playing critical roles in the differentiation of Th cell. As was demonstrated previously, T-bet is a major factor for Th1 cell differentiation and IFN-γ production.\[[@ref21]\] Similarly, *Foxp3* and *RORγt* are the master TFs of nTreg cell and Th17 cell, respectively.\[[@ref9][@ref22]\] *EOMES*, also termed as *TBR2*, encodes a TF which is crucial for embryonic development of the CNS in vertebrates.\[[@ref23]\] Besides, multiple lines of evidences have demonstrated that *EOMES* deeply involves in defense against viral infections.\[[@ref24][@ref25]\] Its function in CD4^+^ Th cell differentiation was remarkably noted recently. A functional experiment revealed that *EOMES* expression directly suppresses the *Rorc* and *IL-17a* expressions through binding to the promoter regions of these genes, which results in suppression of Th17 cell differentiation.\[[@ref26]\]

Meanwhile, *EOMES* expression itself is suppressed by transforming growth factor beta via a Smad-independent pathway in autoimmune disorders.\[[@ref26]\] In addition, a Caucasian population-based mRNA sequencing study further indicated the negative role of *EOMES* dysregulation played in MS progression.\[[@ref12]\] However, more recent functional studies were questioning the role of *EOMES* in some specific conditions. One study even revealed that the higher expression of *EOMES* in Th cell could result in the occurrence of secondary-progressive MS.\[[@ref27]\] Another study conducted by Lupar *et al.*\[[@ref28]\] revealed that the expression of *EOMES* limits the *Foxp3* induction in a cell-intrinsic way. However, more recently, Zhang *et al.*\[[@ref29]\] reported that *EOMES* promotes the development of type 1 regulatory T cells, a *Foxp3*-negative, IL-10-producing T cell subset, which has potent immunosuppressive functions in autoimmunity. Thus, the role of *EOMES* playing in the pathogenesis of MS seems rather complicated and might be divided into two phases, acute phase and chronic phase. The more specific mechanisms of *EOMES* in these two phases remain to be clarified further.

In summary, we have identified a transcription regulation-related variant in Chinese MS patients. This variant is associated with increasing risk. The findings in the current study, together with previous studies, enhanced the knowledge that *EOMES* low expression in the acute phase of RRMS could promote the disease progression. As well, it possibly hints that overexpression of *EOMES* in the acute phase of RRMS might be a potential therapeutic target in RRMS.
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